SIRT6 and neoplasm: Especially, SIRT6-positivity indicated a 4.012 fold greater risk of death of osteosarcoma patients (95% CI, 1.419–11.344; P = 0.009) and had a 4.151 fold greater risk of relapse of tumor or death of patients (95% CI, 1.570-10.971; P = 0.004) (Table 2).